DaVita (DVA)
(Delayed Data from NYSE)
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
Zacks News
Here's Why You Should Hold NextGen (NXGN) in Your Portfolio Now
by Zacks Equity Research
Investor optimism is high on NextGen (NXGN) stock, thanks to solid prospects.
AngioDynamics (ANGO) Shows Solid Results from RAPID Database
by Zacks Equity Research
The RAPID study proved that AngioDynamics' (ANGO) AngioVac System was versatile, safe and effective for the removal of vascular thrombi and cardiac masses.
Is DaVita (DVA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (DVA) Outperforming Other Medical Stocks This Year?
Ecolab Introduces Exelerate TUFSOIL for Food Manufacturers
by Zacks Equity Research
Ecolab's (ECL) Exelerate TUFSOIL has been developed to increase production time and enhance cleaning outcomes to curb food safety risks and improve worker safety.
Becton Dickinson (BDX) Buys Medical Business Assets of CUBEX
by Zacks Equity Research
This should further boost BD's (BDX) Medical segment.
Encompass Health (EHC) to Build Rehabilitation Hub in Illinois
by Zacks Equity Research
Encompass Health (EHC) to construct an inpatient rehabilitation hospital with a capacity of 40 in Shiloh Illinois, which will be run as a joint venture with BJC HealthCare.
Is DaVita HealthCare (DVA) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DVA vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
New Strong Buy Stocks For November 5th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
The Zacks Analyst Blog Highlights: United Natural Foods, The Boston Beer Company, DaVita, Owens & Minor and Primo Water Corp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: United Natural Foods, The Boston Beer Company, DaVita, Owens & Minor and Primo Water Corp
The Zacks Analyst Blog Highlights: FedEx, Whirlpool, The Boston Beer Company, Laboratory Corporation of America and DaVita
by Zacks Equity Research
The Zacks Analyst Blog Highlights: FedEx, Whirlpool, The Boston Beer Company, Laboratory Corporation of America and DaVita
6 Stocks Near 52-Week Highs Poised to Appreciate Further
by Anirudha Bhagat
Investors target stocks that have been on a bullish run, lately. Stocks seeing price strength have higher chances of carrying the momentum ahead.
Acadia Healthcare (ACHC) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Acadia Healthcare (ACHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
5 Safe Stocks to Sail Through the US Election Uncertainties
by Sreoshi Bera
Rise in coronavirus cases and uncertainties revolving around the election might keep markets volatile for some time. Here are five stocks to invest in and play safe.
Wall Street Suffers Back-to-Back Monthly Decline: What Next?
by Nalak Das
At this stage, it will be prudent to invest in large-cap growth/momentum stocks like Zoom Video (ZM), FedEx (FDX), Whirlpool (WHR), The Boston Beer (SAM), Laboratory Corp. (LH), RPM Intetnational (RPM), Brown & Brown (BRO) and DaVita (DVA).
New Strong Buy Stocks For November 2nd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
DaVita (DVA) Earnings Beat Estimates in Q3, Revenues Miss
by Zacks Equity Research
DaVita (DVA) saw strength in dialysis services in the United States in the third quarter.
DaVita HealthCare (DVA) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 20.81% and -0.60%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Healthcare Stock Q3 Earnings Due on Oct 29: NVCR, CRL & More
by Zacks Equity Research
Coronavirus is going to affect the earnings results of healthcare players. While hospitals and health insurers might have suffered the COVID-19 impact, others providing virtual care and COVID-19-related services are likely to have gained from the same.
Are Investors Undervaluing DaVita HealthCare (DVA) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DaVita (DVA) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Solid performance by the net dialysis and related lab patient service segment is likely to have contributed to DaVita's (DVA) top line in the third quarter.
New Strong Buy Stocks for October 26th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.
Analysts Estimate DaVita HealthCare (DVA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (DVA) Outperforming Other Medical Stocks This Year?
DVA vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?